Gotowe bibliografie tematyczne / Osteoarthritis Drugs

Spis treści

  1. Artykuły w czasopismach
  2. Rozprawy doktorskie
  3. Książki
  4. Części książek
  5. Streszczenia konferencji
  6. Raporty organizacyjne

Gotowa bibliografia na temat „Osteoarthritis Drugs”

Autor: Grafiati
Data publikacji: 2 czerwca 2025
Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Osteoarthritis Drugs”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Osteoarthritis Drugs"

1

Ghosh, P. "Chondroprotective drugs and osteoarthritis." Annals of the Rheumatic Diseases 49, no. 5 (1990): 338–39. http://dx.doi.org/10.1136/ard.49.5.338-c.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Matthews, Gloria L., and David J. Hunter. "Emerging drugs for osteoarthritis." Expert Opinion on Emerging Drugs 16, no. 3 (2011): 479–91. http://dx.doi.org/10.1517/14728214.2011.576670.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Russo, Rosita, Valentina Vassallo, Antonietta Stellavato, et al. "Differential Secretome Profiling of Human Osteoarthritic Synoviocytes Treated with Biotechnological Unsulfated and Marine Sulfated Chondroitins." International Journal of Molecular Sciences 21, no. 11 (2020): 3746. http://dx.doi.org/10.3390/ijms21113746.

Pełny tekst źródła
Streszczenie:
Symptomatic slow-acting drugs (SYSADOA) are increasingly used as effective therapies for osteoarthritis, representing an attractive alternative to analgesics or non-steroidal anti-inflammatory drugs to relieve disease symptoms. Pharmaceutical preparations of chondroitin sulfate, derived from animal sources, alone or in combination with glucosamine sulfate, are widely recognized for their beneficial effect on osteoarthritis treatment. A growing interest has also been devoted to understanding the molecular mechanisms modulated by SYSADOA using -omic strategies, most of which rely on chondrocytes
Style APA, Harvard, Vancouver, ISO itp.
4

Sah, Govinda, and Bindu Malla. "Analysis of Prescribing Patterns of Drugs Used in Osteoarthritis in Tertiary Care Center." Journal of Drug Delivery and Therapeutics 14, no. 10 (2024): 10–17. http://dx.doi.org/10.22270/jddt.v14i10.6811.

Pełny tekst źródła
Streszczenie:
Background: Osteoarthritis (O.A.) is a common degenerative lesion of the articular cartilage that corresponds to hypertrophy deterioration of bone structure is osteoarthritis. The treatment is mainly focused on the management of pain. Methods: An Observational study was conducted among 163 patients visiting Orthopedics Out Patient Department at GMC Hospital. The duration of study was for 6 months from Jan 2024-Jun 2024. The analysis of collected data was done by SPSS version Software. Descriptive Statistics tools like frequency, Percentage were used to express the findings. Results: We found t
Style APA, Harvard, Vancouver, ISO itp.
5

Shavlovskaya, O. A. "Bioregulatory drugs in osteoarthritis management." Medical Council, no. 1 (March 6, 2019): 76–83. http://dx.doi.org/10.21518/2079-701x-2019-1-76-83.

Pełny tekst źródła
Streszczenie:
Osteoarthritis (OA) is a degenerative joint disease. Modern theories consider various structural (cartilage destruction) and biophysical disorders (matrix loss of glycosaminoglycans) as the basis of acute and chronic pain syndrome. The main aim of OA therapy is pain relief and functional improvement. To manage pain syndrome in OA it is reasonable to use complex bioregulatory drugs (CBD) (Traumeel S, Zeel T, Discus compositum) both in monotherapy and in combined treatment. The effectiveness of CBD is comparable to that of NSAIDs and CS.
Style APA, Harvard, Vancouver, ISO itp.
6

Meera, Muthu. "Recent advances in the pharmacotherapy of osteoarthritis." Research Results in Pharmacology 8, no. (4) (2022): 167–74. https://doi.org/10.3897/rrpharmacology.8.84951.

Pełny tekst źródła
Streszczenie:
Introduction: Osteoarthritis (OA) is a common debilitating disease affecting the geriatric population. Management of osteoarthritis is a challenge for orthopedicians because till date there has been no such drug that can completely cure the disease or at least retard/arrest the disease progression. In addition to the currently available treatment options for OA like NSAIDs, opioids, nutraceuticals (glucosamine sulphate and chondroitin sulphate), many new drugs are being discovered or repurposed for use in osteoarthritis. Most of these recent drugs aim at retarding the disease progression rathe
Style APA, Harvard, Vancouver, ISO itp.
7

Song, Yingzhuo, Tao Zhang, Huiguang Cheng, et al. "Imidazolium-Based Ionic Liquid-Assisted Preparation of Nano-Spheres Loaded with Bio-Active Peptides to Decrease Inflammation in an Osteoarthritis Model: Ex Vivo Evaluations." Journal of Biomedical Nanotechnology 17, no. 5 (2021): 859–72. http://dx.doi.org/10.1166/jbn.2021.3069.

Pełny tekst źródła
Streszczenie:
Osteoarthritis is one of the most prevalent chronic diseases. Cartilage inflammation in osteoarthritis results from pain in articular joints. Anti-inflammatory drugs provide relief by hindering the production of pro-inflammatory cytokines and interleukin-6. Targeted delivery of anti-inflammatory drugs is very effective in the treatment of osteoarthritis. This approach reduces the usage of therapeutic drug dosages and unwanted side effects. Here, we fabricated a non-invasive and efficient targeted drug delivery system to reduce persistent inflammation in an osteoarthritis model. Temperature-sen
Style APA, Harvard, Vancouver, ISO itp.
8

Park, Junyong, and Sung Won Lee. "Efficacy of disease-modifying osteoarthritis drugs in the treatment of osteoarthritis." Journal of the Korean Medical Association 67, no. 10 (2024): 641–48. http://dx.doi.org/10.5124/jkma.2024.67.10.641.

Pełny tekst źródła
Streszczenie:
Background: Osteoarthritis is the most common form of chronic inflammatory arthritis, and its prevalence is steadily increasing owing to its association with aging. Therefore, understanding and implementing appropriate treatments for osteoarthritis in clinical practice is becoming increasingly important. Additionally, there is active research on a new approach for treating osteoarthritis: disease-modifying osteoarthritis drugs (DMOADs).Current Concepts: Several global osteoarthritis treatment guidelines exist; this article introduces the guidelines of the American College of Rheumatology and O
Style APA, Harvard, Vancouver, ISO itp.
9

Nasreen, Sulthana*and K.Vijaya. "PREVENTION OF NEPHROTOXICITY BY CURCUMIN IN CHEMICALLY INDUCED OSTEOARTHRITIS." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 03 (2018): 1822–30. https://doi.org/10.5281/zenodo.1210845.

Pełny tekst źródła
Streszczenie:
Osteoarthritis is a degenerative disorder resulting in degeneration of cartilage and osteophytes formation. Non steroidal anti inflammatory drugs are commonly used drugs to alleviate the pain in most of the chronic inflammatory conditions like osteoarthritis. These drugs alleviate the pain by inhibiting the synthesis of prostaglandins. Although these drugs reduce the pain, they have several limitations as they cause nephrotoxicity. In recent years several works have been carried out to improve the therapeutic strategy in osteoarthritis. The present study was carried out to investigate the role
Style APA, Harvard, Vancouver, ISO itp.
10

Zvekic-Svorcan, Jelena, Ivana Minakovic, Ksenija Boskovic, Dusica Simic-Panic, Jelena Mikov, and Natasa Igic. "Pharmacological osteoarthritis therapy and modern therapeutic principles." Medical review 75, Suppl. 2 (2022): 47–52. http://dx.doi.org/10.2298/mpns22s2047z.

Pełny tekst źródła
Streszczenie:
Introduction. The purpose of treating osteoarthritis is to relieve pain, improve the function of the osteoarthritic joint, and arrest further development of osteoarthritis through non-pharmacological and pharmacological treatment modalities. Pharmacological osteoarthritis therapy. In the treatment of osteoarthritis, guidelines and recommendations are often consulted, but they do not dictate the treatment mode, which is tailored to the individual needs of the patient. These guidelines promote desired and positive treatment outcomes, but cannot predict a specific outcome. They are also valuable
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Osteoarthritis Drugs"

1

Harry, Diane Sue. "A Markov model for drug response in patients with osteoarthritis /." The Ohio State University, 1985. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487257452615308.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Geiger, Brett Charles. "Designing nanocarriers to penetrate cartilage and improve delivery of biologic drugs for osteoarthritis." Thesis, Massachusetts Institute of Technology, 2019. https://hdl.handle.net/1721.1/121874.

Pełny tekst źródła
Streszczenie:
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biological Engineering, 2019<br>"DOCTOR OF PHILOSOPHY IN BIOLOGICAL ENGINEERING With a focus in Polymers and Soft Matter (PPSM)." Cataloged from PDF version of thesis.<br>Includes bibliographical references (pages 106-112).<br>Osteoarthritis is a debilitating joint disease that affects over 30 million people and has no disease-modifying therapies. The current standard of care for the disease is merely palliative until joint replacement is necessary. Disease-modifying osteoarthritis drugs have been tested in the clinic, but al
Style APA, Harvard, Vancouver, ISO itp.
3

Honcharuk, L. M. "The role of helicobacter infection in gastroduodenopathy induced by nonsteroidal anti-inflammatory drugs in patients with osteoarthritis." Thesis, БДМУ, 2022. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/19610.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Manning, Lauren Brooke. "Experimental Evaluation of Discoid Domain Receptor 2 as an Ideal Target for Development of Disease-Modifying Osteoarthritis Drugs." Thesis, Harvard University, 2015. http://nrs.harvard.edu/urn-3:HUL.InstRepos:17331959.

Pełny tekst źródła
Streszczenie:
Abstract: Osteoarthritis (OA) affects 250 million people worldwide. Currently, no targets for disease-modifying osteoarthritis drugs exist. Matrix metalloproteinase-13 (MMP-13) would make it an ideal target; however, its broad biological effects restrict its application as a target enzyme of inhibitory drugs in the treatment of OA. The expression and activation of discoidin domain receptor 2 (DDR2) is increased in human OA tissues and mouse models of OA and was co-localized with elevated expression of MMP-13 in degenerative articular cartilages. In healthy articular cartilage, DDR2 is kept
Style APA, Harvard, Vancouver, ISO itp.
5

Lomas, Amy. "The renal effects of nonsteroidal anti-inflammatory drugs (NSAIDS) in dogs with chronic kidney disease (CKD)." Thesis, Kansas State University, 2013. http://hdl.handle.net/2097/20475.

Pełny tekst źródła
Streszczenie:
Master of Science<br>Department of Clinical Sciences<br>Gregory F. Grauer<br>Prostaglandins play many important roles in the kidney including regulation of renal blood flow, glomerular filtration, renin release, and sodium excretion. Upon activation of the renin angiotensin aldosterone system (RAAS), prostaglandin upregulation becomes critical to offset the vasoconstrictive effects of norephinephrine, angiotensin II, and vasopressin. Nonsteroidal anti-inflammatory drugs (NSAIDs) produce both their beneficial and detrimental effects through inhibition of the cyclooxygenase enzyme and subse
Style APA, Harvard, Vancouver, ISO itp.
6

Swenson, Victor, and Mattias Ekberg. "Usage of Non-steroidal anti-inflammatory drugs in a sample of New Zealanders with osteoarthritis : A cross-sectional study." Thesis, Umeå universitet, Avdelningen för fysioterapi, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-171613.

Pełny tekst źródła
Streszczenie:
Introduction Oral Non-steroidal anti-inflammatory drugs (NSAID) is an analgesia and is commonly used by people with osteoarthritis (OA). Oral NSAID is currently recommended as the second level of treatment for OA, and could be considered if physical activity, topical NSAID or paracetamol do not supply sufficient pain relief.   Aim To investigate how frequently oral NSAID is used in a sample of New Zealanders with OA and also to investigate the exposure to heightened risk of adverse events while using oral NSAID.   Method A cross-sectional survey was conducted to collect information about the u
Style APA, Harvard, Vancouver, ISO itp.
7

Honcharuk, I. M. "The role of pathogenic strains helicobacter pylori in gastroduodenopathies induced by non-steroidal anti-inflammatory drugs in patients with osteoarthritis." Thesis, БДМУ, 2021. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/18587.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Sobko, D. I. "Blood pressure changes as a result of taking nonsteroidal anti-inflammatory drugs among the patients who suffer from osteoarthritis with concomitant hypertension." Thesis, БДМУ, 2020. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/18060.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Allas, Lyess. "Méthylation de H3K27 : régulation et rôle dans le cartilage articulaire Development of a simple osteoarthritis model useful to predict in vitro the anti-hypertrophic action of drugs." Thesis, Normandie, 2019. http://www.theses.fr/2019NORMC426.

Pełny tekst źródła
Streszczenie:
L’arthrose est la maladie rhumatologique la plus répandue et une des causes majeures de douleur et de handicap. Au cours de ce travail nous avons étudié le rôle et la régulation de la tri-méthylation de la lysine 27 de l’histone H3 (H3K27me3) dans l’arthrose et la chondrogenèse.Dans une première partie, nous avons montré que l’inhibition de la méthylase EZH2 par l’EPZ-6438 atténue l’inflammation et la libération de métalloprotéases par les chondrocytes traités à l’IL-1β. L’inhibition d’EZH2 réduit également l’hypertrophie des chondrocytes induite par le TGF-β1. L’EZP-6438 attenue aussi la dégr
Style APA, Harvard, Vancouver, ISO itp.
10

Pimentel, Thais Spacov Camargo. "Revisão sistemática: tratamento da osteoartrose com uso de antiinflamatórios não esteroidais em cães." Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/5/5160/tde-12062013-115529/.

Pełny tekst źródła
Streszczenie:
INTRODUÇÃO: A terapia farmacológica de escolha para o tratamento de cães com osteoartrose é o uso de antiinflamatórios não esteroidais. Porém, sua eficácia no controle dos sinais clínicos apresentados pelos animais ainda não foi bem estabelecida em três revisões sistemáticas anteriormente publicadas. OBJETIVOS: Avaliar a qualidade metodológica dos ensaios clínicos randomizados controlados sobre o uso dos antiinflamatórios não esteroidais (AINEs) para o tratamento da dor nos cães com osteoartrose; identificar a melhor opção terapêutica; os principais efeitos adversos envolvidos na sua administr
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Osteoarthritis Drugs"

1

Bales, Peter. Osteoarthritis: Preventing and healing without drugs. Prometheus Books, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

G, Lombardino J., ed. Nonsteroidal antiinflammatory drugs. Wiley, 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Brandt, Kenneth D. Diagnosis and nonsurgical management of osteoarthritis. 2nd ed. Professional Communications, Inc., 2000.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

1951-, Reid David, and Miller Colin G. 1960-, eds. Clinical trials in rheumatoid arthritis and osteoarthritis. Springer, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

L, Hardy Mary, Southern California Evidence-Based Practice Center/RAND., and United States. Agency for Healthcare Research and Quality., eds. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Agency for Healthcare Research and Quality, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

R, Cook Allan, ed. Arthritis sourcebook: Basic information about specific forms of arthritis and related disorders including rheumatoid arthritis, osteoarthritis, gout, polymyalgia rheumatica, psoriatic arthritis, spondyloarthropathies, juvenile rheumatoid arthritis, and juvenile ankylosing spondylitis along with treatment options from over-the-counter and prescription drugs to surgery and alternative measures and coping strategies to ease pain, fatigue, and stress. Omnigraphics, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Maetzel, Andreas. The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis. Canadian Coordinating Office for Health Technology Assessment, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Brenda, Adderly, and Fox Barry, eds. The arthritis cure: The medical breakthrough that can halt, reverse, and even cure osteoarthritis. Century, 1997.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Brenda, Adderly, and Fox Barry, eds. The arthritis cure: The medical miracle that can halt, reverse, and may even cure osteoarthritis. St. Martin's Press, 1997.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Brenda, Adderly, and Fox Barry, eds. The arthritis cure: The medical miracle that can halt, reverse, and may even cure osteoarthritis. St. Martin's Paperbacks, 1997.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Osteoarthritis Drugs"

1

Rodríguez-Merchán, E. Carlos, Hortensia De la Corte-Rodríguez, and Juan M. Román-Belmonte. "Initial Treatment of Knee Osteoarthritis: Oral and Topical Drugs." In Comprehensive Treatment of Knee Osteoarthritis. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-44492-1_1.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Raiss, Ruth. "Safety Pharmacology of Drugs with Osteoarthritis-Related Activity." In Drug Discovery and Evaluation. Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/3-540-29804-5_12.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Reginster, Jean-Yves, and Roy D. Altman. "Slow-Acting Drugs for the Treatment of Osteoarthritis." In Modern Therapeutics in Rheumatic Diseases. Humana Press, 2002. https://doi.org/10.1007/978-1-59259-239-5_12.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Walker, F. S., and K. D. Rainsford. "Do NSAIDs Adversely Affect Joint Pathology in Osteoarthritis?" In Side Effects of Anti-Inflammatory Drugs IV. Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5394-2_6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Bellamy, N. "Measuring Beneficial and Adverse Events in Osteoarthritis Clinical Trials." In Side Effects of Anti-Inflammatory Drugs IV. Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5394-2_5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Ehrlich, G. E. "Treatment Decisions, Side-Effect Liability and Cost-Effectiveness in Osteoarthritis." In Side Effects of Anti-Inflammatory Drugs IV. Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5394-2_4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Reginster, J. Y., B. Avouac, and C. Gosset. "Clinical Evaluation of Drug Therapy." In Osteoarthritis. Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-60026-5_22.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Förster, K. K. "Drug Treatment of Osteoarthritis: Clinical Aspects." In Osteoarthritis. Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-87752-0_6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Roubille, Camille, Jean-Pierre Pelletier, and Johanne Martel-Pelletier. "Drug/Agent Treatments for Osteoarthritis: Present and Future." In Osteoarthritis. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-19560-5_10.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Dingle, J. T. "Non-steroidal, Anti-inflammatory Drug Administration in the Treatment of Osteoarthritis." In Osteoarthritis. Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-60026-5_19.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Osteoarthritis Drugs"

1

Nogueira-Recalde, U., F. J. Blanco, M. I. Loza, et al. "SAT0053 Identification of novel drugs with senolytic activity as osteoarthritis therapeutics." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3680.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Vina, Ernest, Michael Hannon, Jazmin Dagnino, and C. Kent Kwoh. "THU0624 UNDERSTANDING ETHNIC DIFFERENCES IN THE UTILIZATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS FOR OSTEOARTHRITIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.4401.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Xu, Xiaxia, and Ruth Wittoek. "AB0815 THE INFLUENCE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON INFLAMMATORY SONOGRAPHIC FEATURES IN EROSIVE HAND OSTEOARTHRITIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.3625.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Loisay, L., S. Bouagga, A. Antoniadis, T. Hügle, and J. Geurts. "POS0794 ANTI-DIABETIC DRUGS TARGET SUBCHONDRAL MARROW ADIPOSE TISSUE METABOLISM IN A PRECLINICAL MODEL OF KNEE OSTEOARTHRITIS." In EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria. BMJ Publishing Group Ltd and European League Against Rheumatism, 2024. http://dx.doi.org/10.1136/annrheumdis-2024-eular.6122.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Persson, M. S. M., A. Sarmanova, M. Doherty, and W. Zhang. "AB0969 Conventional and biologic disease modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomised controlled trials." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.4592.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Persson, Monica, Joanne Stocks, Aliya Sarmanova, et al. "THU0447 THE RELATIVE EFFICACY OF TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND CAPSAICIN IN OSTEOARTHRITIS: MOVING FROM AVERAGE TREATMENT EFFECTS TO INDIVIDUAL TREATMENT PREFERENCES." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.699.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Atiquzzaman, Mohammad, Ehsan Karim, Hubert Wong, Jacek Kopec, Mary De Vera, and Aslam Anis. "SAT0600 COMPARATIVE CARDIOVASCULAR SAFETY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AMONG INDIVIDUALS WITH OSTEOARTHRITIS; FINDINGS FROM PROVINCIAL PRESCRIPTION CLAIM RECORDS IN BRITISH COLUMBIA, CANADA." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.1145.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Nieminen, Heikki J., Ari Salmi, Jari Rinta-aho, et al. "MHz ultrasonic drive-in: Localized drug delivery for osteoarthritis therapy." In 2013 IEEE International Ultrasonics Symposium (IUS). IEEE, 2013. http://dx.doi.org/10.1109/ultsym.2013.0160.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Carames, B., U. Nogueira-Recalde, MI Loza, FJ Blanco, and E. Dominguez. "FRI0005 Targeting cartilage aging as osteoarthritis therapeutics by drug repurposing." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.3658.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Förster, KK, and KW Schmid. "AB0147 Drug treatment of osteoarthritis: aspects of symptom and structure modification." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.409.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Osteoarthritis Drugs"

1

Huang, Zeling, Xiao Mao, Junming Chen, et al. Sinomenine hydrochloride injection for knee osteoarthritis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.11.0057.

Pełny tekst źródła
Streszczenie:
Review question / Objective: At present, many clinical studies have been reported on the treatment of KOA by injecting sinomenine hydrochloride into the knee cavity. However, no systematic evaluation has been published on this issue, and it is not clear whether sinomenine hydrochloride injection is effective and safe in the treatment of KOA.Therefore, it is important to conduct systematic evaluation to obtain relatively convincing conclusions as to whether sinomenine hydrochloride injection can be a good choice as a complementary and alternative drug (CAM) for KOA. Condition being studied: The
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Osteoarthritis Drugs” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii